Prophylactic and therapeutic vaccines for infectious diseases

Vaxinano is at the forefront of developing innovative nasal vaccines utilizing its proprietary STELLAR-NP technology. This advanced mucosal and nasal vaccine platform is built on bio-sourced nanoparticles that have been optimized over 30 years for high penetration efficiency into mucosal barriers. These nanoparticles are capable of loading various antigens, including proteins, mRNA, and inactivated pathogens, and can effectively activate the immune system without the need for adjuvants. The unique properties of these nanoparticles allow them to cross mucus barriers and deliver antigens directly to immune cells via a simple nasal spray, making them particularly suitable for use in developing countries where cold chain storage may be a challenge.

In addition to its vaccine delivery technology, Vaxinano specializes in the optimization of pathogenic strains for vaccine development, focusing on diseases such as toxoplasmosis and leishmaniasis. The company has developed a robust pipeline that includes a prophylactic vaccine for Toxoplasma, an immunotherapeutic treatment for Leishmania, and a prophylactic vaccine for E. coli. Vaxinano's commitment to safety is evident in its use of inactivated pathogens in its formulations, which reduces risks associated with live-attenuated vaccines. With over 30 years of experience in vaccine discovery and manufacturing, Vaxinano is equipped with specialized bioproduction units to support its innovative vaccine development efforts.

France

Vaxinano is a biotechnology company specializing in the pre-clinical and clinical development of human and veterinary vaccines. Vaxinano was created in 2016, based on 30 years of research and clinical trials in vaccinology using technology patented by Pr. Didier Betbeder.

Our approach is based on a unique and innovative antigen delivery system using bio-compatible, adjuvant-free and safe-by-design nanoparticles.

Vaxinano

Company Details